Phase 2Completed
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (LAZURE)
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 in Combination With Rosuvastatin on Low Density Lipoprotein Cholesterol in Participants With Dyslipidaemia (LAZURE)
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 76 enrolled
- Conditions
- Dyslipidaemia
- Interventions
- Placebo; AZD0780; Rosuvastatin
- Ages
- adults, older adults
- Registry
- NCT07218900
Full record on ClinicalTrials.gov
From the registry
This is a study to investigate the effect of AZD0780 tablets on low density lipoprotein cholesterol levels (LDL-C) compared with placebo tablets administered in combination with rosuvastatin tablets in adult Russian participants with dyslipidaemia. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to 136 days, including a screening period of up to 14 days, rosuvastatin run-in period of 28 days, treatment with AZD0780 or placebo for 84 days, and a safety follow-up period of 10 days.
Primary outcomes
- Relative change in Low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks
History
Last registry update
Primary completion
Started
Registered